Mr Jonathan RobinsonSenior Director Scientific Affairs
Mr David LustigVice President, Business Development
Enesi Pharma Limited
Mr David HipkissChief Executive Officer
Dr Ludovic BonnetVP Product Development
Image Analysis Group
IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development. IA‘s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.
Dr Diana RoettgerHead of Scientific and Medical Affairs
MGB Biopharma Ltd
MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.
Dr Miroslav RavicCEO
Mr Raymond SpencerCFO
OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology.